万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://onlinelibrary.wiley.com/journal/14455994
3、投稿网址：http://mc.manuscriptcentral.com/imj
4、官网邮箱：imj@racp.edu.au（编辑部）
5、官网电话：+61 2 9256 5431（主编）
6、期刊刊期：月刊，一年出版12期。
2021年7月7日星期三
投稿须知【官网信息】
Author Guidelines
MANUSCRIPT SUBMISSION
Thank you for your interest in Internal Medicine Journal. Please read the complete Author Guidelines carefully prior to submission, including the section on copyright. To ensure fast peer review and publication, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.
Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at http://mc.manuscriptcentral.com/imj
We look forward to your submission.
EDITORIAL AND CONTENT CONSIDERATIONS
Aims and Scope
The Internal Medicine Journal (IMJ) is the official journal of internal medicine of the Adult Medicine Division of The Royal Australasian College of Physicians. Its purpose is to publish high-quality, internationally competitive peer-reviewed, original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The journal also has a major role in continuing medical education and publishes review articles relevant to physician education. Research work relating exclusively to paediatrics may be best submitted to the College’s paediatric publication, the Journal of Paediatrics and Child Health.
Peer review
Except where otherwise stated, manuscripts are single-blind peer reviewed by anonymous reviewers. The Editor and Publisher reserve the right to modify manuscripts to eliminate ambiguity and repetition, and to improve communication between author and reader.
The Editorial Board reserves the right to refuse any material for publication.
For more information on review confidentiality policy, please visit:
https://authorservices.wiley.com/Reviewers/journal-reviewers/tools-and-resources/review-confidentiality-policy.html
ETHICAL CONSIDERATIONS
Conflict of Interest Disclosure
In accordance with the policies of The Royal Australasian College of Physicians, the Internal Medicine Journal requires that all authors disclose any potential financial or other conflict of interest in discussion with the corresponding author at submission stage. A modified Conflict of Interest form has been adapted from the International Committee of Medical Journal Editors (ICMJE) for the Internal Medicine Journal. The corresponding author only is responsible for signing and completing a single ICMJE form on behalf of all authors for each submission. The form is in four parts.
Publication of articles cannot proceed until the disclosure form has been completed and signed by the corresponding author. Authors can download the COI form when accessing their Author centre on ScholarOne Manuscripts. Log in access is required.
Principles for Publication of Research Involving Human Subjects
Manuscripts must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the Declaration of Helsinki (as revised in Brazil 2013), available at https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under the study should be omitted.
In general, submission of case studies should be accompanied by the written consent of the subject (or parent/guardian) prior to publication; this is particularly important where photographs are to be used or in cases where the unique nature of the incident reported makes it possible for the patient to be identified. While the editors recognise that it might not always be possible or appropriate to seek such consent, the onus will be on the authors to demonstrate that this exception applies in their case.
If the patient is deceased, in their cover letter authors should comment on their efforts to get consent from a patient's next of kin or other responsible individuals but failure to achieve consent does not necessarily preclude consideration of the paper provided there is not active objection from those approached.
Clinical Trials Registration
The journal requires that the clinical trials submitted for its consideration are registered in a publicly accessible database. Authors should include the name of the trial register and their clinical trial registration number in the ‘Acknowledgements’ section of their manuscript. If you wish the editor[s] to consider an unregistered trial, please explain briefly why the trial has not been registered.
Trials should be registered at or before the onset of patient enrolment. This policy applies to any clinical trial starting enrolment after July 1, 2008. For trials that began enrolment before this date, we request registration by December 1, 2008, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials) are exempt.
We do not advocate one particular registry, but registration with a registry that meets the following minimum criteria:
(1) accessible to the public at no charge;
(2) searchable by standard, electronic (Internet-based) methods;
(3) open to all prospective registrants free of charge or at minimal cost;
(4) validates registered information;
(5) identifies trials with a unique number; and
(6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).
Registries that meet this criteria include but are not limited to the below:
(1) the registry sponsored by the United States National Library of Medicine (http://www.clinicaltrials.gov);
(2) the International Standard Randomized Controlled Trial Number Registry (http://www.controlled-trials.com);
(3) the Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au);
(4) the Chinese Clinical Trial Registry (http://www.chictr.org.cn/enindex.aspx);
(5) the Clinical Trials Registry—India (http://ctri.nic.in);
(6) University hospital Medical Information Network (UMIN) (http://www.umin.ac.jp/ctr/).
Research reporting guidelines
Authors are encouraged to use the relevant research reporting guidelines for the study. This will ensure that you provide enough information for editors, peer reviewers and readers to understand how the research was performed and to judge whether the findings are likely to be reliable. The key reporting guidelines are:
Randomised controlled trials (RCTs): CONSORT guidelines
Systematic reviews and meta-analyses: PRISMA guidelines and MOOSE guidelines
Observational studies in epidemiology: STROBE guidelines and MOOSE guidelines
Diagnostic accuracy studies: STARD guidelines
Quality improvement studies: SQUIRE guidelines
Sponsored research
In keeping with College policy, research sponsored directly by tobacco companies will not be considered for publication.
Use of Animals in Research
Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to Australian National Guidelines for animal usage in research.
Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria: i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; ii) Drafting the work or revising it critically for important intellectual content; iii) Final approval of the version to be published; and i) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.
Committee on Publication Ethics
The journal is a member of, and subscribes to the principles of the Committee on Publication Ethics (COPE).
Data Sharing and Data Accessibility
The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.
Plagiarism Detection
The journal employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.
Publication Ethics
This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.
MANUSCRIPT CATEGORIES AND WORD LENGTH
In view of current pressures on editorial space, we insist that papers comply with the prescribed word length for article categories. Note that word length refers to the main text of the article. Articles that exceed the prescribed article word length will be withdrawn at submission stage.
Editorials are invited papers offering authoritative views/perspectives and can be either standalone or complement another paper in the same or another issue. Although editorials are usually honed around a specialised topic, they should be pitched at the journal’s general physician readership. A length of 1500 words and a maximum of 20 references is recommended; inclusion of one table or headings is at the editor’s discretion.
Original Articles should not exceed 3000 words and should be arranged under the usual headings of Abstract (less than 250 words), Introduction, Methods, Results, Discussion, Conclusion and References. Papers with poor methodology or poor execution (eg. too many patients lost to follow up) are unlikely to be accepted. Prospective studies are more likely to be accepted than retrospective studies, but only with solid methodology.
Fast track publications should report research findings of international significance which give new insights into the mechanism of a particular disease or have a potential to alter medical practice. Authors may request consideration for fast tracking. Papers not accepted for fast tracking will be considered as standard publications at the author’s request.
A Brief Communication is a concise paper which reports a significant finding. The main text is typically 1600 words, including a short unstructured abstract no longer than six lines. Only a single heading for Discussion is included and there can be no more than two tables with a maximum of 20 references cited. Brief Communications may be accompanied by supplementary information.
Letters to the Editor should not exceed 500 words. Short relevant comments on medical and scientific issues, particularly controversies, are encouraged. We encourage authors who submit letters of comment on papers published in the Journal to provide their own article title. Authors will be offered right of reply (no more than 500 words) at the discretion of the Editor and discussion will not be entered into. Reply letters are co-published with the original letter of comment in an issue. We point out that it is Journal style to publish invited reply letters under the one heading of 'Reply'. To ensure that each letter is self contained and complete for citation purposes, authors who submit invited replies should reference both their original work and the letter which comments on their work. Given the current pressures on editorial space, invited comments are restricted to one reply.
Case Reports (Clinical scientific notes) are published only if the report is of exceptional interest (i.e. it makes a unique point) with clear proof of cause and effect. Case reports are to be restricted to 500 words plus six references, with only one figure or table. Case reports are published under the subcategory of Clinical-scientific notes which appear under the generic category of Letters to the Editor.
Reviews are usually solicited. The Editorial Board is open to suggestions for appropriate topics to consider and these should be directed to the relevant subspecialty editor or the Deputy Editor-in-Chief via the Editorial office. Communications should be sent stating the article title, co-author names and affiliations and a brief abstract. Reviews must come from an author who is not acting on behalf of a company and the relationship with any sponsor must be clearly explained at submission time. The policy of the Journal is to publish high-quality review material covering both medical research and practice. An emphasis on evidence based data is important. Studies that comply with evidence based medicine principles are more likely to be accepted. Comprehensive and short reviews are considered. Categories include: (i) Comprehensive Reviews of up to 3500 words and 35 references, (ii) Short Reviews of up to 1500 words and 20 references, (iii) Clinical Perspectives: practical updates of management in major medical disorders of up to 3000 words and 20 references and (iv) short Systematic Reviews with a maximum length of 3500 words. Authors wishing to submit them should check with the subspecialty editor first for suitability of the proposed topic. Papers in this category will be considered as Original Research articles and the methodology of the review specifically evaluated. (v) Current Controversies are of up to 1500 words plus 20 references. In this section attempts will be made to present opposing viewpoints.
Position Papers Major management issues from authoritative specialist societies. These will usually be condensed versions or extracts of larger published statements with a short unstructured abstract and will run to a maximum of 1500 words plus 20 references. Background material relating to specific recommendations should, as far as possible, appear as explanatory notes after each recommendation rather than in a separate background statement.
Images in Medicine This series is closed until further notice.
Reports of clinicopathological conferences and hypotheses will be considered if of outstanding merit.
Personal Viewpoint Articles of up to 2000 words giving a perspective on current aspects of medical practice but not suitable for publication as scientific articles. A maximum of 20 references is suggested and a brief abstract.
History in Medicine Narrative articles of up to 2000 words describing doctors in history, historical aspects of medicine/medical practice and which are not suitable for publication as scientific articles. A maximum of 20 references is suggested and a brief abstract.
Ethics in Medicine Series Papers are solicited. In general, articles are clinically oriented. They should be no more than 1500 words with a maximum of eight references. Authors should first contact the Editorial Office.
How I Treat: This series offers an individualistic opinion (not necessarily evidence based) on how to treat a disorder. A word limit of 1500 words with a maximum of 30 references is appropriate. Articles can be either solicited or offered.
PREPARATION OF THE MANUSCRIPT
Pre-acceptance English-language editing
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. Visit our site to learn about the options. All services are paid for and arranged by the author. Please note using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal.
Optimising Your Article for Search Engines
Many students and researchers looking for information online will use search engines such as Google, Yahoo or similar. By optimising your article for search engines, you will increase the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in another work. We have compiled these guidelines to enable you to maximise the web-friendliness of the most public part of your article.
Manuscript style
Manuscripts should follow the style of the Vancouver agreement detailed in the ICMJE's revised ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication’, as presented at http://www.ICMJE.org/
Spelling should conform with the Concise Oxford Dictionary. (For example, use 's' not 'z'.)
Measurements and abbreviations. All measurements must be given in SI units as outlined in the latest edition of Units, Symbols and Abbreviations: A Guide for Authors and Editors, 6th edition. Edited by D.N. Baron and H. Mckenzie Clarke (Royal Society of Medicine Press, London, 2008). Statistics and measurements should always be given in numerals (i.e. 10 mm), except where the number begins a sentence. When a number does not refer to a unit of measurement it is spelt out, except where the number is greater than nine.
Acronyms and Abbreviations should be used sparingly and only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation. (Abbreviations such as e.g. and i.e. should only be used in parentheses.) A list of acronyms should be provided for original articles, reviews and brief communications. Acronyms in shorter submissions can be left in the body of the paper.
Drugs should be referred to by their generic names, rather than brand names.
Genes. Human genes are upper case and italicised, mouse genes are lower case and italicised; the protein products of human genes are upper case and not italicised. Example: BRAF for the gene and BRAF for the protein product.
Parts of the Manuscript
The manuscript should be submitted in separate files: title page; main text file; figures.
Title page
The title page should contain the following:
(i) A short informative title that contains the major key words. The title should not contain abbreviations.
(ii) Author details, including: the full names of the authors and positions they hold at the time of submission of the manuscript (note that only author affiliations, not author titles, are published in the final article.) The author's institutional affiliations at which the work was carried out. In keeping with the latest guidelines of the ICMJE, each author’s contribution to the paper is to be quantified (see section on Authorship and Acknowledgements above for details).
(iv) The full postal and email address, plus telephone number, of the author to whom correspondence about the manuscript should be sent.
(v) Acknowledgements. The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors’ industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Personal thanks and thanks to anonymous reviewers are not appropriate.
(vi) The word count of both the abstract and main text. (Note that in particular, authors must adhere to the prescribed length for articles, especially Original Articles and Reviews. Original Articles and Reviews may be returned to authors before being considered, if the page length is far in excess of the prescribed limit)
(vii) abstract and key words.
The present address of any author, if different from that where the work was carried out, should be supplied in a footnote.
Abstract and key words
Each original research paper should carry a structured abstract of not more than 250 words presented in the following form. Background: Brief statement of relevant work or clinical situation, and hypothesis, if applicable. Aims: Brief statement of the overall aim. Methods: Laboratory or other techniques used, including statistical analysis. Outcome measures clearly stated. Results: Statistically significant results and relevant negative data cited. Conclusions: Referable to the aims of the study and may include suggestions for future action. Five key words in order of importance for indexing purposes should be supplied below the abstract and should be taken from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list at http://www.nlm.nih.gov/ meshhome.html.
Only a short, unstructured abstract is required for Reviews and Brief Communications. General Correspondence letters do not require an abstract.
Main text
The main text of the manuscript should be presented in the following order: (i) text, (ii) references, (iii) figure legends, (iv) tables (each table on a separate page and complete with title and footnotes), (v) appendices. Figures and supporting information should be submitted as separate files.
Text
Authors should use subheadings to divide sections of their manuscript: Introduction, Materials and Methods, Results, Discussion, Acknowledgements, Conclusion and References. The Methods section should carry a statement confirming clearance of the study by an approved institutional ethics committee. Statistical methods used must be specified.
……
更多详情：
https://onlinelibrary.wiley.com/page/journal/14455994/homepage/forauthors.html
